Johnson & Johnson acquires Intra-Cellular Therapies

NEW BRUNSWICK, N.J. - Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Intra-Cellular Therapies, Inc., integrating it as a new business unit within its Innovative Medicine division, the company announced today. The acquisition includes CAPLYTA® (lumateperone), an FDA-approved treatment for schizophrenia and bipolar depression in adults, and a promising clinical-stage pipeline targeting generalized anxiety disorder and Alzheimer’s disease-related psychosis.

CAPLYTA® is notable for being the only FDA-approved treatment for depressive episodes associated with bipolar I and II disorder as both monotherapy and adjunctive therapy. Additionally, a supplemental new drug application (sNDA) for CAPLYTA® as an adjunctive treatment for major depressive disorder (MDD) was accepted by the FDA in February 2025, with the potential to set a new standard of care for common depressive disorders.

The acquisition is expected to boost Johnson & Johnson’s sales growth by about 0.8% in 2025, contributing around $0.7 billion in incremental sales. Despite initial expectations of a $0.30 to $0.35 per share dilution in earnings, the company now forecasts a lesser impact of $0.25 per share for 2025 and $0.21 per share in 2026. These estimates will be included in the full-year financial outlook to be reported on April 15, 2025.

Joaquin Duato, Chairman and CEO of Johnson & Johnson, expressed enthusiasm for the acquisition, stating, "We are excited to officially welcome the talented Intra-Cellular Therapies team to the Company, and we look forward to working together as we realize our ambition of becoming the number one neuroscience company worldwide."

Jennifer Taubert, Executive Vice President at Johnson & Johnson, emphasized the strategic importance of the acquisition for near- and long-term growth, highlighting the company’s commitment to transforming treatment and patient care for neuropsychiatric and neurodegenerative disorders.

Following the completion of the transaction, Intra-Cellular Therapies’ common stock ceased trading on the NASDAQ Global Select Market. This move is part of Johnson & Johnson’s broader strategy to innovate across targeted therapeutic areas, with neuroscience being a key focus.

This news article is based on a press release statement.

In other recent news, Johnson & Johnson is set to finalize its acquisition of Intra-Cellular Therapies, following shareholder approval. This acquisition is projected to contribute approximately $0.7 billion in sales growth for 2025, though it will initially dilute earnings per share by about $0.25. Meanwhile, Johnson & Johnson’s attempts to resolve talc-related lawsuits through bankruptcy have been rejected for the third time by a U.S. judge, allowing claimants to proceed with jury trials. This decision has been a significant legal hurdle for the company as it seeks to address ongoing litigation claims.

Despite these challenges, both TD Cowen and UBS have maintained their Buy ratings for Johnson & Johnson, with respective price targets of $185 and $180. The analysts acknowledge the legal setbacks but remain optimistic about the company’s financial health and stock performance. Johnson & Johnson has indicated it may return to traditional litigation to address the lawsuits, having experienced some prior court victories. The company has yet to respond to the latest legal ruling but is expected to outline its next steps soon.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.